As pathogen molecular diagnostics technology develops, the software analysis of polymerase chain reaction (PCR) sigmoidal curves, crossing threshold (Ct) values and the limit of nucleic acid detection for that assay, is not always available when reporting test results. These are critical components in interpreting results and can affect the management of patients. Our view is that all commercial assay providers must ensure users, as they can with laboratory developed tests, are able to see the curve and Ct value for all samples. Some examples demonstrating this principle are included. Regulatory bodies have a key role to play.

中文翻译：

---

任由 AI 算法摆布 – 不一致的 PCR 结果


随着病原体分子诊断技术的发展，在报告检测结果时，聚合酶链反应 （PCR） S 形曲线、交叉阈值 （Ct） 值和该检测的核酸检测限的软件分析并不总是可用。这些是解释结果的关键组成部分，可以影响患者的管理。我们认为，所有商业检测提供商都必须确保用户能够看到所有样品的曲线和 Ct 值，就像他们可以通过实验室开发的检测一样。包括一些演示此原理的示例。监管机构可以发挥关键作用。